ArticleInfection and immunity1996
Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection.
Article in Infection and immunity, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 95 citations in OpenAlex.
- Purification and Characterization of Immunoglobulin Y (IgY) Targeting Surface Antigen 1 (SAG1) ofAntibodies (Basel, Switzerland) · 2025Article
- Targeted Delivery ofFrontiers in immunology · 2018Article
- Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route.Medical microbiology and immunology · 2017Article
- Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii.Parasitology research · 2017Article
- Recent advances in Toxoplasma gondii immunotherapeutics.The Korean journal of parasitology · 2014Review
- Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii.Parasites & vectors · 2014Review
- Article
- Molecular cloning, sequencing, and biological characterization of GRA4 gene of Toxoplasma gondii.Parasitology research · 2013Article
- Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis.PloS one · 2013Article
- Cholera toxin: a paradigm of a multifunctional protein.The Indian journal of medical research · 2011Review
- Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function.The Journal of experimental medicine · 2009Article
- Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris.Parasitology research · 2007Article
- Effect of rSAG-1(P30) immunisation on the circulating and tissue parasites in guinea pigs as determined by quantitative PCR.Parasitology research · 2006Article
- Synergistic role of micronemal proteins in Toxoplasma gondii virulence.The Journal of experimental medicine · 2005Article
- Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis.Clinical and diagnostic laboratory immunology · 2004Article
- The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis.Infection and immunity · 2003Article
- Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.Journal of virology · 2002Article
- Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.Infection and immunity · 2001Article
- Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model.Infection and immunity · 2000Article
- Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments.Infection and immunity · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SAG1 protein of Toxoplasma gondii was evaluated as a protective antigen in mucosal immunization with cholera toxin as an adjuvant. CBA/J mice intranasally immunized with a combination of SAG1 and cholera toxin exhibited significantly fewer cysts in the brain after oral infection with the 76K strain of T. gondii than control mice. This acquired protection lasted at least 5 months. Protected mice developed high levels of serum anti-SAG1 immunoglobulin G antibodies as well as an enhanced systemic cellular response, as assessed by the proliferation of splenocytes in response to SAG1 restimulation in vitro. This cellular proliferation was associated with an increase of interleukin-2 and interleukin-5 synthesis and with barely detectable gamma interferon production. Splenic immune T cells were shown to convey modest protection to recipients against development of brain cysts following oral infection with T. gondii. Significant production of anti-SAG1 immunoglobulin A was induced in intestinal secretions of protected mice. These results indicate that intranasal immunization with SAG1 and cholera toxin can induce mucosal and systemic immune responses and affords partial and long-lasting resistance against the establishment of chronic toxoplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.